CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 80.96% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

SkinHealth Systems Q3 revenue beats estimates

By Reuters News


Overview

  • US medical aesthetics firm's Q3 revenue fell yr/yr but beat analyst expectations

  • Q3 adjusted EBITDA beat analyst expectations, reflecting improved operational efficiency

  • Company retired its 2026 debt as planned


Outlook

  • Company sees 2026 net sales of $281 mln to $287 mln

  • Company expects 2026 adjusted EBITDA of $48 mln to $50 mln


Result Drivers

  • CONSUMABLES GROWTH - Co said consumables sales returned to growth in Q3

  • GROSS MARGIN IMPROVEMENT - Co attributed higher gross margin to lower inventory charges and tariff-related recoveries

  • LOWER OPERATING EXPENSES - Co said reduced personnel and professional fees drove lower operating expenses


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Sales

Beat

$69.20 mln

$67.78 mln (9 Analysts)

Q3 Net Loss

$900,000

Q3 Adjusted EBITDA

Beat

$13.40 mln

$6.02 mln (9 Analysts)


Analyst Coverage

  • The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 6 "hold" and 2 "sell" or "strong sell"

  • The average consensus recommendation for the personal products peer group is "buy."

  • Wall Street's median 12-month price target for Skinhealth Systems Inc is $12.50, about 13.1% above its November 4 closing price of $11.05


Reuters Recommended Reads

  • Nov 4 - Coty tops estimates on prestige brands boost amid turnaround

  • Nov 4 - Estee Lauder sets 2030 growth, margin targets as turnaround advances

  • Nov 5 - Elf sees Q2 sales boost with marketing, Europe expansion


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.